Swedish Orphan Biovitrum AB (Sobi) has completed the acquisition of CTI BioPharma Corp., a specialized international biopharmaceutical company, through its indirect wholly owned subsidiary Cleopatra Acquisition Corp, in a transaction valued at $1.7 billion. As a result of the transaction, CTI has become an indirect wholly owned subsidiary of Sobi, and the common stock of CTI will cease to be traded on the NASDAQ Stock Market. CTI is a commercial biopharmaceutical company focused on the dev...